Skip to main content
SpringerLink
Log in

mCRC: Erhaltungstherapie lohnt sich

  • Literatur kompakt_Gastrointestinale Tumoren
  • Published:
Im Focus Onkologie Aims and scope

Profitieren Patienten mit metastasiertem kolorektalem Karzinom nach der Induktionstherapie von einer Kombination von Chemotherapie und zielgerichteter Behandlung mit Bevacizumab?

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Judith Neumaier

  2. Klinik für Allgemeine Innere Medizin, Onkologie / Hämatologie, Gastroenterologie und Infektiologie, Klinikum Esslingen, Esslingen, Deutschland

    Michael Geißler

Authors
  1. Judith Neumaier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Geißler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Geißler.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Neumaier, J., Geißler, M. mCRC: Erhaltungstherapie lohnt sich. Im Focus Onkologie 18, 35–36 (2015). https://doi.org/10.1007/s15015-015-2068-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-015-2068-7

Search

Navigation